<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20250708066412N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2025-11-01</date_registration>
      <primary_sponsor>Zanjan University of Medical Sciences</primary_sponsor>
      <public_title>The comparison of the effectiveness of online group therapy and in-person therapy on depression and anxiety in patients with MS (Multiple Sclerosis).</public_title>
      <acronym></acronym>
      <scientific_title>Effectiveness of Online vs. In-Person Unified Protocol Group Therapy on Transdiagnostic Components in Patients with Multiple Sclerosis Comorbid with Depression and Anxiety</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2025-07-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>40</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/85158</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Based on the selection criteria, a sample size of 40 individuals has been determined, all of whom are members of the MS Association in Zanjan. The sample will be selected using a convenience sampling method according to the inclusion criteria and will be randomly assigned to two groups: virtual intervention and online intervention. Each of these groups will be further divided into two subgroups of ten individuals. The two intervention groups will receive in-person and online therapy, respectively. Each group will consist of 20 individuals, Blinding description: In this trial, due to the nature of the interventions (online therapy versus in-person therapy), blinding of the participants and therapists was not feasible. The participants and therapists are naturally aware of the type of intervention they are receiving or delivering. However, to minimize bias in the outcome assessment and data analysis, a method of "outcome assessor and data analyst blinding" was employed.

Outcome assessors, who were responsible for collecting primary outcome data (such as scores on psychological questionnaires, functional assessments, etc.), were kept unaware of the participants' group allocation.

The individual or team who performed the final statistical analyses were unaware of the identity of the groups (i.e., which statistical code corresponded to the "online" group and which to the "in-person" group). The data provided to the analysts were labeled with neutral codes (e.g., "Group A" and "Group B"). The linkage between these codes and the actual group identities was only revealed after the completion of the primary statistical analyses, for the purpose of drafting the results.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Multiple Sclerosis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: In-Person Transdiagnostic Cognitive-Behavioral Therapy (Unified Protocol)**  The intervention will be delivered in person using the Transdiagnostic Cognitive-Behavioral Therapy (Unified Protocol) for adults. This protocol consists of eight modules to be implemented over a minimum of 12 sessions. The modules include: (1) goal setting and maintaining motivation, (2) understanding emotions, (3) emotional mindfulness, (4) cognitive flexibility, (5) emotional behavior, (6) understanding and confronting bodily sensations, (7) emotion exposure, and (8) reviewing skills while progressing toward goals and maintaining achievements.  The protocol primarily focuses on emotions and their three fundamental components: thoughts, bodily sensations, and behaviors. Within the thought component, emphasis is placed on identifying cognitive errors and cognitive restructuring. The bodily sensation component incorporates techniques to enhance awareness of physical sensations. For the behavior component, participants learn about emotional triggers and opposite action strategies. The intervention culminates with techniques for confronting situational emotions and conducting behavioral experiments. All modules will be delivered across 12 weekly sessions, each lasting 45 minutes, spanning approximately 12 weeks. Intervention 2: Intervention group: Online Transdiagnostic Cognitive-Behavioral Therapy (Unified Protocol)The intervention will be delivered online using the Transdiagnostic Cognitive-Behavioral Therapy (Unified Protocol) for adults. This protocol consists of eight modules to be implemented over 12 sessions. The modules include: (1) goal setting and maintaining motivation, (2) understanding emotions, (3) emotional mindfulness, (4) cognitive flexibility, (5) emotional behavior, (6) understanding and confronting bodily sensations, (7) emotion exposure, and (8) reviewing skills while progressing toward goals and maintaining achievements.The protocol primarily focuses on emotions and their three fundamental components: thoughts, bodily sensations, and behaviors. Within the thought component, emphasis is placed on identifying cognitive errors and cognitive restructuring. The bodily sensation component incorporates techniques to enhance awareness of physical sensations. For the behavior component, participants learn about emotional triggers and opposite action strategies. The intervention culminates with techniques for confronting situational emotions and conducting behavioral experiments. All modules will be delivered across 12 sessions, each lasting 45 minutes, spanning approximately 6 weeks with twice-weekly sessions.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is No more information</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Elahe karami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dr. Beheshti Hospital, Darvazeh Ark</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1331713161</zip>
        <telephone>+98 992 061 7285</telephone>
        <email>eliikaramiii@gmail.com</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Elahe karami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dr. Beheshti Hospital, Darvazeh Ark</address>
        <city>Zanjan</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1331713161</zip>
        <telephone>+98 992 061 7285</telephone>
        <email>eliikaramiii@gmail.com</email>
        <affiliation>Zanjan University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Diagnosis of Multiple Sclerosis
Minimum literacy level (at least middle school education)
No history of addiction
No other psychological treatments received during the study
Age between 20 and 40 years
No acute psychiatric disorders
No severe physical disability, such as dependence on a wheelchair
Score between 0 and 16 on the BDI-II (Beck Depression Inventory-II)
Score between 0 and 25 on the BAI (Beck Anxiety Inventory)</inclusion_criteria>
      <agemin>20 years</agemin>
      <agemax>40 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Development of severe psychiatric disorders
Relapse of the disease or severe physical disability
Development of severe physical disability (such as wheelchair dependence) during the study
Absence from more than two sessions
Recent experience of an acute psychological crisis
Score higher than 16 on the BDI-II
Score higher than 25 on the BAI</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>G35</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Multiple Sclerosis</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: In-Person Transdiagnostic Cognitive-Behavioral Therapy (Unified Protocol)**  The intervention will be delivered in person using the Transdiagnostic Cognitive-Behavioral Therapy (Unified Protocol) for adults. This protocol consists of eight modules to be implemented over a minimum of 12 sessions. The modules include: (1) goal setting and maintaining motivation, (2) understanding emotions, (3) emotional mindfulness, (4) cognitive flexibility, (5) emotional behavior, (6) understanding and confronting bodily sensations, (7) emotion exposure, and (8) reviewing skills while progressing toward goals and maintaining achievements.  The protocol primarily focuses on emotions and their three fundamental components: thoughts, bodily sensations, and behaviors. Within the thought component, emphasis is placed on identifying cognitive errors and cognitive restructuring. The bodily sensation component incorporates techniques to enhance awareness of physical sensations. For the behavior component, participants learn about emotional triggers and opposite action strategies. The intervention culminates with techniques for confronting situational emotions and conducting behavioral experiments. All modules will be delivered across 12 weekly sessions, each lasting 45 minutes, spanning approximately 12 weeks.</i_keyword>
      <i_keyword>Intervention group: Online Transdiagnostic Cognitive-Behavioral Therapy (Unified Protocol)The intervention will be delivered online using the Transdiagnostic Cognitive-Behavioral Therapy (Unified Protocol) for adults. This protocol consists of eight modules to be implemented over 12 sessions. The modules include: (1) goal setting and maintaining motivation, (2) understanding emotions, (3) emotional mindfulness, (4) cognitive flexibility, (5) emotional behavior, (6) understanding and confronting bodily sensations, (7) emotion exposure, and (8) reviewing skills while progressing toward goals and maintaining achievements.The protocol primarily focuses on emotions and their three fundamental components: thoughts, bodily sensations, and behaviors. Within the thought component, emphasis is placed on identifying cognitive errors and cognitive restructuring. The bodily sensation component incorporates techniques to enhance awareness of physical sensations. For the behavior component, participants learn about emotional triggers and opposite action strategies. The intervention culminates with techniques for confronting situational emotions and conducting behavioral experiments. All modules will be delivered across 12 sessions, each lasting 45 minutes, spanning approximately 6 weeks with twice-weekly sessions.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Fear of Disease Progression. Timepoint: Measurements will be conducted at three time points: before the intervention (baseline), immediately after the intervention completion (post-treatment), and three months after the intervention completion (3-month follow-up). Method of measurement: The individual's score on the Fear of Disease Progression Questionnaire (FoP-Q).</prim_outcome>
      <prim_outcome>Perceived Stress. Timepoint: Measurements will be conducted at three time points: before the intervention (baseline), immediately after the intervention completion (post-treatment), and three months after the intervention completion (3-month follow-up). Method of measurement: The participant's score on the Cohen Perceived Stress Scale (PSS).</prim_outcome>
      <prim_outcome>Intolerance of Uncertainty. Timepoint: Measurements will be conducted at three time points: before the intervention (baseline), immediately after the intervention completion (post-treatment), and three months after the intervention completion (3-month follow-up). Method of measurement: The respondent's Intolerance of Uncertainty Scale (IUS) score.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Depresion. Timepoint: Measurements will be conducted at three time points: before the intervention (baseline), immediately after the intervention completion (post-treatment), and three months after the intervention completion (3-month follow-up). Method of measurement: BDI Questionnaire score.</sec_outcome>
      <sec_outcome>Anxiety. Timepoint: Measurements will be conducted at three time points: before the intervention (baseline), immediately after the intervention completion (post-treatment), and three months after the intervention completion (3-month follow-up). Method of measurement: BAI Questionnaire score.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Zanjan University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2025-01-20</approval_date>
        <contact_name>Zanjan University of Medical Sciences</contact_name>
        <contact_address>Zanjan University of Medical Sciences Mahdavi Street Karmandan Town Zanjan, Iran Zanjan Zanjan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
